CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
In short, its a gradual process, not an overnight change
Patients should not use Tesamorelin or growth hormone-related peptides without a review of labs, medical history, medications, glucose markers, cancer history, and body composition goals
Tesamorelin copies GHRH and binds GHRH receptors on the pituitary
10mg per dose Primary Benefits Provides targeted, clean growth hormone stimulation through ghrelin receptor activation without affecting cortisol or prolactin levels
